Trial Profile
Phase 2 Trial of 3-2,4 Dimethoxybenzylidene Anabaseine [GTS 21] in Schizophrenia.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 31 Jan 2020
Price :
$35
*
At a glance
- Drugs GTS 21 (Primary)
- Indications Schizophrenia
- Focus Therapeutic Use
- Acronyms DMXB-A
- 27 Jan 2020 Status changed from recruiting to completed.
- 04 Dec 2017 According to ClinicalTrials.gov, the recruitment status of this study is unknown because the information has not been verified recently (last verified 4 Dec 2015)
- 04 Dec 2015 Planned End Date changed from 1 Dec 2012 to 1 Dec 2016 as per ClinicalTrials.gov record.